logo

For the Inventor, By the Inventor

Berlin, Germany

Martin Krueger

This inventor holds 14 USPTO granted patents and 1 published patent application and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Schering Aktiengesellschaft, Bayer Schering Pharma Ag, Bayer Intellectual Property Gmbh. Active years: 2006-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin Krueger. Retrieved from https://idiyas.com/inventor/martin-krueger-o74j4x7a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 7.2

ph-index = 4

Forward Citations = 41(Granted Patents)


Company Filing History:

goldMedal6 out of 1,409 
 
Schering Aktiengesellschaft
 patents
silverMedal5 out of 192 
 
Bayer Schering Pharma Ag
 patents
bronzeMedal2 out of 721 
 
Bayer Intellectual Property Gmbh
 patents
4. 1 out of 3,978 
 
Novartis Ag
 patents

Years Active: 2006-2014

Loading Chart...
Loading Chart...
Areas of Expertise:
VEGF Inhibitors
Protein Kinase Inhibitors
Pharmaceutical Compositions
Anthranilamide Derivatives
Pyridine Compounds
Dihydropyridine Derivatives
Sulfoximine Compounds
Nicotinamide Pyridinureas
Medicinal Uses
Pharmaceutical Agents
Alkynylpyrimidines
Azanthranylalkyl Amides
14 patents (USPTO):Explore Patents
1. 8642611 - Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same (2014-02-04),
2. 8198456 - Dihydropyridine derivatives as useful as protein kinase inhibitors (2012-06-12),
3. 8003655 - Substituted sulphoximines as TIE2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same (2011-08-23),
4. 7906533 - Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors (2011-03-15),
5. 7902229 - Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors (2011-03-08),
6. 7572794 - Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors (2009-08-11),
7. 7517894 - VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines (2009-04-14),
8. 7479491 - Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors (2009-01-20),
9. 7459470 - N-oxide anthranylamide derivatives and their use as medicaments (2008-12-02),
10. 7429592 - Cyanoanthranilamide derivatives and the use thereof as medicaments (2008-09-30),
11. 7338958 - Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents (2008-03-04),
12. 7202260 - VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones (2007-04-10),
13. 7081468 - Ortho-substituted anthranilic acid amides and their use as medicaments (2006-07-25),
14. 7012081 - Anthranyl amides and their use as medicaments (2006-03-14),

Title: Innovations and Contributions of Inventor Martin Krueger

Introduction

Martin Krueger, based in Berlin, Germany, is a distinguished inventor recognized for his significant contributions in the field of pharmaceuticals. With a total of 14 patents to his name, Krueger has made substantial advancements through his innovative research and development efforts.

Latest Patents

Two of Martin Krueger's latest patents highlight his expertise and dedication to improving healthcare. The first patent concerns alkynylpyrimidines and their salts, which are pharmaceutical compositions aimed at addressing diseases related to dysregulated vascular growth. These compounds are particularly notable for their ability to interfere with Tie2 and VEGFR2 signaling pathways, offering potential treatments for various vascular growth disorders.

The second recent patent focuses on dihydropyridine derivatives that serve as effective protein kinase inhibitors. This innovation identifies novel compounds exhibiting protein tyrosine kinase inhibitory activity, which could be utilized for treating c-Met-mediated diseases or conditions, adding to the arsenal of therapeutic options available in modern medicine.

Career Highlights

Throughout his career, Martin Krueger has worked with reputable companies in the pharmaceutical industry, including Schering Aktiengesellschaft and Bayer Schering Pharma AG. His experience with these leading firms has equipped him with valuable insights into drug development and the complexities of patenting innovative medical solutions.

Collaborations

Krueger has also collaborated with notable colleagues such as Andreas Huth and Martin Haberey. These partnerships have not only facilitated the advancement of his inventions but have significantly contributed to the collective knowledge in the fields of pharmacology and biotechnology.

Conclusion

Martin Krueger's relentless pursuit of innovation has led to meaningful advancements in pharmaceutical science. His patents showcase his commitment to addressing critical health issues and exemplify the vital role that inventors play in developing new treatment modalities. The impact of his work will likely resonate in the industry for years to come, as these innovations continue to pave the way for enhanced healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…